^
Association details:
| Biomarker: | TP53 mutation + LRP1B mutation + TMB-H |
|---|---|
| Cancer: | Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P14.07 - Clinically Predictive Value of Plasma Cell-Free DNA in Lung Cancer Immunotherapy
Published date:
01/12/2021
Excerpt:
TP53 co-mutation affected 100% LRP1B and 100% FANCM. TP53/LRP1B and TP53/FANCM co-altered patients were found with higher bTMB than TP53/LRP1B and TP53/FANCM wild-type (median 13.44 vs. 6.72, Mann-Whitney test, p = 0.0058)...TP53/LRP1B and TP53/FANCM co-mutations were associated with high bTMB and ICI response rate.
